Details of the Drug

General Information of Drug (ID: DM2FJE7)

Drug Name

NDI-034858

Synonyms

Zasocitinib; NDI-034858; C293MNS6TQ; 2272904-53-5; UNII-C293MNS6TQ; TAK-279; Pyrazolo(1,5-a)pyrimidine-3-carboxamide, N-((1R,2R)-2-methoxycyclobutyl)-7-(methylamino)-5-((2-oxo(1(2H),2'-bipyridin)-3-yl)amino)-; (8S)-N-[(1R,2R)-2-methoxycyclobutyl]-7-(methylamino)-5-{[(1P,2'P)-2-oxo-2H-[1,2'-bipyridin]-3-yl]amino}pyrazolo[1,5-a]pyrimidine-3-carboxamide; N-((1R,2R)-2-Methoxycyclobutyl)-7-(methylamino)-5-((2-oxo-2H-[1,2'-bipyridin]-3-yl)amino)pyrazolo[1,5-a]pyrimidine-3-carboxamide; zasocitinib [INN]; TAK279; SCHEMBL20678921; GTPL12155; BDBM424361; EX-A7221; NDI034858; US10508120, Compound I-816; US10508120, Compound I-908; MS-28444; HY-150096; CS-0609920; compound I-908 [US20190256519A1]; F96153; N-[(1R,2R)-2-methoxycyclobutyl]-7-(methylamino)-5- [(2-oxo[1(2H),2'-bipyridin]-3-yl)amino]-pyrazolo[1,5- a]pyrimidine-3-carboxamide; N-[(1R,2R)-2-methoxycyclobutyl]-7-(methylamino)-5-[(2-oxo-1-pyridin-2-ylpyridin-3-yl)amino]pyrazolo[1,5-a]pyrimidine-3-carboxamide; ZSB

Indication

Disease Entry	ICD 11	Status	REF
Psoriatic arthritis	FA21	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecule

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C23H24N8O3
Canonical SMILES: CNC1=CC(=NC2=C(C=NN12)C(=O)NC3CCC3OC)NC4=CC=CN(C4=O)C5=CC=CC=N5
InChI: InChI=1S/C23H24N8O3/c1-24-20-12-18(27-16-6-5-11-30(23(16)33)19-7-3-4-10-25-19)29-21-14(13-26-31(20)21)22(32)28-15-8-9-17(15)34-2/h3-7,10-13,15,17,24H,8-9H2,1-2H3,(H,27,29)(H,28,32)/t15-,17-/m1/s1
InChIKey: BWINBHTTZLVXGT-NVXWUHKLSA-N

Cross-matching ID

PubChem CID: 137441492
TTD ID: D5XJ7F

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
TYK2 tyrosine kinase (TYK2)	TTBYWP2	TYK2_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT05153148) A Phase 2b, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Subjects With Active Psoriatic Arthritis. U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of Nimbus Therapeutics